TLDR PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
The PRIDE syndrome, associated with the use of Epidermal Growth Factor Receptor (EGFR) inhibitors, encompassed a range of dermatological side effects including papulopustules, paronychia, regulatory abnormalities of hair growth, itching, and dryness. The study highlighted the need for awareness and management of these adverse effects in patients undergoing cancer treatment with EGFR inhibitors. The authors, M.E. Lacouture and S.E. Lai, from the Cancer Skin Care Program and SERIES Clinic at Northwestern University, emphasized the importance of dermatological care in improving the quality of life for these patients.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
252 citations
,
November 1995 in “The EMBO Journal” Blocking EGFR in mice causes hair loss and skin changes.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
19 citations
,
October 2011 in “Clinics in Dermatology” New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
